Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome (CHOP-OR)
The purpose of this study is to evaluate Ofatumumab in combination with CHOP (cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone/prednisolone, the standard chemotherapy treatment) in induction and maintenance treatment of Richter's Syndrome. This study aims to evaluate the overall response rate to CHOP-O (CHOP in combination with Ofatumumab) according to the Revised Response Criteria for Malignant Lymphoma. The hypothesis would be that treatment with CHOP-O for Richter's Syndrome (RS), shows a difference in overall survival (more people living longer), when compared with the standard treatment of CHOP-R (CHOP chemotherapy plus Rituximab).
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome|
- Objective response [ Time Frame: Week 20 ] [ Designated as safety issue: No ]
Objective response as defined by the revised response criteria for malignant lymphoma (Cheson et al, JCO, Vol 25, No 5, 2007).
Patients will be classified as responders/non-responders as follows: complete remission (CR), nodular partial remission (nPR) and partial remission (PR) are classified as responders; while stable disease (SD) and progressive disease (PD) are classified as non-responders. Non-evaluable patients will be classified as non-responders.
- Overall survival [ Time Frame: 72 weeks ] [ Designated as safety issue: No ]Overall survival where length of survival is defined in whole days as the time from entry into the study until death from any cause. For those who are not observed to die during the course of the trial will be censored at their last known follow-up date.
- Progression free survival [ Time Frame: 72 weeks ] [ Designated as safety issue: No ]Progression free survival where length of survival is defined in whole days as the time from entry into the study until lymphoma progression or death from any cause. For those who are not observed to progress or die during the course of the trial will be censored at their last known progression-free follow-up date
- Duration of response [ Time Frame: 72 weeks ] [ Designated as safety issue: No ]Duration of response defined in whole days as the time between recorded response to disease progression or death from any cause. Patients will be censored at the date of their last follow-up visit at which the response was assessed.
- Time to next DLBCL therapy [ Time Frame: 72 weeks ] [ Designated as safety issue: No ]Time to next DLBCL therapy defined in whole days as the time from the end of study treatment and the start of the next DLBCL therapy other than CHOP in combination with ofatumumab. Patients will be censored at the date of their last follow-up visit at which the further treatment was assessed.
- Reduction in Tumour Size [ Time Frame: 13, 20 and 72 weeks ] [ Designated as safety issue: No ]Reduction in Tumour Size will be measured by the absolute value of and percentage change in the sum of products of the diameters of the largest abnormal lymph nodes from screening to post-baseline computerised tomography (CT) scans. CT scans will be complemented by positron emission tomography (PET) scanning in patients with bulky (>5cm) lymphadenopathy from B-CLL.
- Patient reported outcomes [ Time Frame: Baseline, week 13, week 20, every 2 months until week 72 and at week 72. ] [ Designated as safety issue: No ]Patient reported outcomes these will be assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire) and the EORTC QLQ-CLL16 at baseline and regular follow-up visits throughout the trial.
- Safety [ Time Frame: Throughout trial and up to 4 weeks post end of treatment ] [ Designated as safety issue: Yes ]Safety - Adverse events (AE) and abnormal clinical and laboratory findings will be collected at all follow-up visits and up to 4 weeks post end of treatment.
|Study Start Date:||April 2011|
|Estimated Study Completion Date:||September 2014|
|Estimated Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Single arm study
1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.
Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks
Other Name: Arzerra
Richter's Syndrome (RS) is a high-grade transformation that occurs in 5-15% of patients with B cell chronic lymphocytic leukaemia (B-CLL). RS is a complication of B-CLL in which the leukemia changes into a fast-growing diffuse large B cell lymphoma (DLBCL). The pathogenesis (mechanism by which the disease is caused) of RS is poorly understood and predictors of transformation and response to treatment are unknown. Management of RS remains unsatisfactory; the mean overall survival of patients treated with conventional chemo-immunotherapy such as CHOP-R is 8 months from the end of treatment.
CHOP is the acronym for a chemotherapy regimen, cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone/prednisolone) and the R stands for the monoclonal antibody, Rituximab. Ofatumumab, a next generation monoclonal anti CD20 antibody, has proven single agent activity in relapsed/refractory B-CLL and other non-Hodgkin lymphomas. In addition, it has shown a favourable safety profile in the maintenance setting.
Therefore, we propose to evaluate Ofatumumab in combination with CHOP in induction and maintenance treatment of patients with RS.
The primary objective of the study will be to evaluate overall response rate (ORR) to CHOP-O (CHOP chemotherapy plus Ofatumumab) according to the Revised Response Criteria for Malignant Lymphoma (Cheson).
Secondary objectives will be feasibility of recruitment, progression free survival and overall survival, the clinical benefit and changes in patient reported outcome measures, safety and tolerability.
This is a multi-centre non-randomised Phase II National Cancer Research Institute (NCRI) feasibility study in 35 patients with newly diagnosed Richter's Syndrome in the UK. CHOP-O will be given for six cycles followed by six cycles of Ofatumumab maintenance treatment every eight weeks and a three months follow-up period. The total duration of recruitment will be 24 months starting from the opening of the first site.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01171378
|Contact: Anna Schuh, MD, PhD, MRCP, FRCPath||01865 firstname.lastname@example.org|
|Contact: Anne Francis, DPhil||01865 email@example.com|
|Queen Elizabeth Hospital Birmingham||Recruiting|
|Birmingham, United Kingdom, B15 2TT|
|Principal Investigator: Jim Murray|
|Sub-Investigator: Paul Moss|
|Royal Bournemouth Hospital||Recruiting|
|Bournemouth, United Kingdom, BH7 7DW|
|Principal Investigator: David Oscier|
|Sub-Investigator: Joseph Chacko|
|Sub-Investigator: Rachel Hall|
|Sub-Investigator: Helen McCarthy|
|Sub-Investigator: Renata Walewska|
|Cambridge, United Kingdom, CB2 0QQ|
|Principal Investigator: George Follows|
|St James University Hospital||Recruiting|
|Leeds, United Kingdom, LS9 7TF|
|Principal Investigator: Peter Hillmen|
|Sub-Investigator: Anne Critchley|
|Sub-Investigator: Anita Hill|
|Sub-Investigator: Rod Johnson|
|Sub-Investigator: Roger Owen|
|Royal Liverpool University Hospital||Recruiting|
|Liverpool, United Kingdom, L7 8XP|
|Principal Investigator: Andrew Pettitt|
|Sub-Investigator: Nagesh Kalakonda|
|St Bartholomew's Hospital||Recruiting|
|London, United Kingdom, EC1A 7BE|
|Principal Investigator: John Gribben|
|Sub-Investigator: Samir Agwaral|
|Kings College Hospital||Recruiting|
|London, United Kingdom, SE5 9RS|
|Principal Investigator: Stephen Devereux|
|Manchester, United Kingdom, M20 4BX|
|Principal Investigator: Adrian Bloor|
|Oxford, United Kingdom, OX3 7LJ|
|Principal Investigator: Anna Schuh, MD, PhD, MRCP, FRCPath|
|Sub-Investigator: Graham Collins|
|Sub-Investigator: Chris Hatton|
|Principal Investigator:||Anna Schuh, MD, PhD, MRCP, FRCPath||Oxford University Hospitals NHS Trust|